Temsirolimus

This classification denotes a mtor inhibitor with the molecular formula C56H87NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 624KN6GM2T, chemically known as rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) but generally known as temsirolimus, which bears US NIH Compound Identifier 6440033. European Medicines Agency schedules Temsirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21308. The term TEMSIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 3, 2005, List 54). World Health Organization schedules temsirolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule temsirolimus under HS 29349990 and SITC 51579. As of Q4 2014, TEMSIROLIMUS remains the US FDA Preferred Term for this commodity. Temsirolimus bears US NLM identifiers UMLS ID C1707080 and NCI Concept Code C1844. SMILES: O(C1CC(CCC1OC(=O)C(CO)(CO)C)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)C.